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Several steps of the HDL-mediated reverse choles-
terol transport (RCT) are transcriptionally regulated
by the nuclear receptors LXRs in the macrophages,
liver, and intestine. Systemic LXR activation via
synthetic ligands induces RCT but also causes
increased hepatic fatty acid synthesis and steatosis,
limiting the potential therapeutic use of LXR ago-
nists. During the last few years, the participation of
the intestine in the control of RCT has appeared
more evident. Here we show that while hepatic-
specific LXR activation does not contribute to RCT,
intestinal-specific LXR activation leads to decreased
intestinal cholesterol absorption, improved lipopro-
tein profile, and increased RCT in vivo in the absence
of hepatic steatosis. These events protect against
atherosclerosis in the background of the LDLR-defi-
cient mice. Our study fully characterizes the molec-
ular and metabolic scenario that elects the intestine
as a key player in the LXR-driven protective environ-
ment against cardiovascular disease.
INTRODUCTION
In the reverse cholesterol transport (RCT) pathway, excess
cholesterol fluxed from peripheral cells to HDL is transported
to the liver for subsequent elimination as bile acids and neutral
steroids (Rader, 2003). While LDL, formed by the metabolism of
very low-density lipoproteins (VLDLs), and chylomicron remnant
particles are considered proatherosclerotic (Zilversmit, 1979),
HDLs are considered antiatherogenic due to their ability to stim-
ulate RCT (Linsel-Nitschke and Tall, 2005; Rader, 2002) and to
their antioxidant and anti-inflammatory properties (Navab et al.,
2000). At molecular level, one of the first steps of RCT is medi-
ated by ATP-binding cassette (ABC) transporter A1 (ABCA1),
which effluxes phospholipids and cholesterol from cell mem-Celbrane to lipid-poor ApoAI to generate pre-bHDL (Oram and
Vaughan, 2000). HDL further acquires cholesterol via ABCG1-
and SR-BI-mediated efflux (Klucken et al., 2000; Wang et al.,
2004).
Liver X receptors (LXRs) a (NR1H3) and b (NR1H2), members
of the nuclear receptor transcription factor family, are critical for
the control of lipid homeostasis and respond to physiological
concentrations of sterols (Janowski et al., 1996; Willy and
Mangelsdorf, 1997). Activation of LXR by synthetic agonists
reduces the body load of cholesterol by stimulating the RCT
pathway through the induction of a wide range of target genes
such as ABCA1, ABCG1, ABCG5, ABCG8, and apolipoprotein
E (ApoE) (Repa et al., 2000b, 2002; Venkateswaran et al.,
2000; Laffitte et al., 2001). However, the potential for LXR ago-
nists as treatment option for atherosclerosis (Joseph et al.,
2002; Terasaka et al., 2003; Kratzer et al., 2009) is hampered
by the activation of key genes critical for hepatic de novo
lipogenesis (Repa et al., 2000a; Schultz et al., 2000). Hence,
systemic LXR activation induces RCT but also causes hypertri-
glyceridemia and hepatic steatosis (Grefhorst et al., 2002).
Recently, the participation of intestine in the regulation of RCT
has become more evident, with the crucial role of this organ for
the maintenance of plasma HDL (Brunham et al., 2006a; Brun-
ham et al., 2006b) and the direct secretion of plasma-derived
cholesterol into the intestinal lumen (van der Velde et al., 2007),
both processes improved by LXR activation. Hence, new strate-
gies aimed to specifically target LXR in the intestine were pro-
posed in order to avoid the hepatic steatosis observed after acti-
vation of LXR in the liver. In this study, we provide evidence that
the constitutive activation of LXRa in the intestinal epithelium
reduces atherosclerosis by decreasing intestinal cholesterol
absorption, improving lipoprotein composition, and stimulating
RCT without hepatic lipid accumulation.
RESULTS
Intestinal LXR Decreases Cholesterol Absorption
and Induces RCT
To elucidate the role of selective intestinal LXR activation in lipid
metabolism and atherosclerosis, we generated a transgenicl Metabolism 12, 187–193, August 4, 2010 ª2010 Elsevier Inc. 187
Figure 1. Characterization of iVP16LXRa
Transgenic Mice
(A) Expression of LXRa target genes in the intes-
tine of iVP16LXRa was measured by real-time
quantitative PCR. ABCG5, ABCG8, and ABCA1
mRNA levels were upregulated in the intestine of
iVP16LXRa. The results are shown as mean ±
SEM (n = 6 for each genotype).
(B) Fractional cholesterol absorption of iVP16LXRa
versus iVP16 mice. Intestinal cholesterol absorp-
tion was measured using the fecal dual-isotope
method as described in the Supplemental Experi-
mental Procedures and shows a 40% reduction
in iVP16LXRa compared to control mice.
(C) Increased fecal neutral sterol excretion was
measured in iVP16LXRa compared to iVP16
mice as described in the Supplemental Experi-
mental Procedures.
(D) The rates of in vivo cholesterol synthesis in the
liver and kidney (extrahepatic control tissue) were
measured 60 min after intraperitoneal injection of
3H-water precursor. Reduced cholesterol absorp-
tion determines a compensatory increase in liver
cholesterol biosynthesis. The results are shown
as mean ± SEM (n = 6 for each genotype).
(E) Box and whisker plots of plasma total
cholesterol measurements with the bottom and the top of the boxes representing the 25th and 75th percentile, i.e., lower and upper quartile, respectively,
and the band near the middle of the box representing the 50th percentile, i.e., median, and the ends of the whiskers the minimum and the maximum of all
the data for a total of n = 12 mice.
(F) Box and whisker plots of cholesterol HDL measurements of n = 12 mice.
(G) HDL subclasses in iVP16LXRa and iVP16. HDL subclasses were separated by two-dimensional gel electrophoresis in pre-b and a migrating particles and
transferred onto a nitrocellulose membrane, which were detected with an anti-apolipoprotein A-I antibody.
(H) Box and whisker plots of pre-bHDL fractions as percent of total Apo A-I. of n = 12 mice.
(I) Intestinal-specific LXR activation impact on macrophage-specific cholesterol transport (RCT) in vivo. Macrophage-derived 3H-cholesterol content (from left to
right) in plasma, liver, bile, and feces was measured by liquid scintillation counting. Data analysis shows that intestinal-specific LXR activation is able to induce
macrophage-mediated RCT resulting in augmented fecal cholesterol removal. The results are shown as mean ± SEM (n = 6 for each genotype) and are ex-
pressed as percent of radioactivity injected. *p < 0.05 iVP16LXRa versus VP16.
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(VP16LXRa) was under the control of the enterocyte-specific
Villin promoter (Madison et al., 2002). As controls, transgenic
mice specifically expressing in the intestine VP16 (iVP16) were
generated. iVP16LXRa mice were fertile and were born at the
expected Mendelian frequencies. iVP16LXRa mice expressed
the VP16LXRa in the entire length of the intestine (see Figures
S1A and S1B available online). To confirm the functionality of
the VP16LXRa transgene expression, we measured the mRNA
and protein expression of known LXR target genes in the intes-
tine. As shown in Figure 1A, ABCG5, ABCG8, and ABCA1
mRNA levels (Figure 1A), as well as ABCA1 protein (Figures
S1B and S1D), were upregulated in the intestine of iVP16LXRa.
Tissue-specific activation of the LXR-mediated transcriptional
machinery was confirmed by the absence of modulation of
LXR target genes ABCG5 and ABCG8 in the liver of transgenic
mice (Figure S1E).
The induction of ABCG5 and ABGC8 in iVP16LXRa mice was
accompanied by a 40% reduction in cholesterol absorption
compared to control iVP16 mice (Figure 1B). The reduction in
cholesterol absorption was coupled with an increase in fecal
neutral sterol excretion (Figure 1C) and can be also explained
by the LXR-driven reduction in NPC1L1 mRNA levels (Fig-
ure S1C) (Duval et al., 2006). As a compensatory physiologic
response, hepatic cholesterol synthesis increases in conditions
of reduced intestinal cholesterol absorption (Repa et al., 2005).188 Cell Metabolism 12, 187–193, August 4, 2010 ª2010 Elsevier IncConsistently, in vivo de novo hepatic cholesterol synthesis was
significantly increased by 25% in iVP16LXRa mice compared
to control iVP16 mice (Figure 1D). Unchanged cholesterol
synthesis observed in the kidney (Figure 1D) confirmed the
hepatic selective adaptive response. In line with these results,
hepatic genes involved in cholesterol biosynthesis, i.e., SREBP2,
HMG-CoA synthase, and HMG-CoA reductase, were up-
regulated in the liver of iVP16LXRa mice Figure S1E. Thus,
intestinal selective LXR activation results in reduced intestinal
cholesterol absorption and increased hepatic de novo choles-
terol synthesis.
To investigate the metabolic effect of selective LXR activation
in the intestine, we first analyzed plasma cholesterol levels in
lipoproteins. iVP16LXRa displayed an increase in total choles-
terol levels (Figure 1E) and HDL cholesterol particles (Figure 1F).
Moreover, two-dimensional gel electrophoresis showed a sig-
nificant increase in the preb-HDL fraction (Figures 1G and 1H),
highlighting the important contribution of the intestine to the
synthesis of these particles. To test whether the preb-HDL
formation could lead to increased RCT, we carried out an
in vivo study in which 3H-cholesterol-labeled J774 cells were
peritoneally injected into iVP16LXRa and control iVP16 mice.
As shown in Figure 1I, biliary and fecal 3H-cholesterol levels
were increased while 3H-bile acid levels were unchanged, sug-
gesting that in iVP16LXRa mice bile acid synthesis was unaf-
fected, as also confirmed by the unaltered CYP7A1mRNA levels.
Figure 2. Hepatic-Specific LXR Activation
Does Not Affect RCT
(A) Significant upregulation of LXR target genes
ABCG5, ABCG8, SREBP1c, FAS, and SCD1 was
observed in the liver of mice infected with
AdVP16LXRa compared to control AdVP16
infected mice.
(B) Intestinal gene expression levels of LXR targets
ABCA1, ABCG5, and ABCG8 did not change after
AdVP16 and AdVP16LXRa infection, thus under-
lining the hepatic-specific LXR activation.
(C) Serum and hepatic cholesterol and TG levels
were measured in AdVP16 and AdVP16LXRa
infected mice. Data show increased TG levels in
both serum and liver with a trend toward a reduc-
tion in hepatic cholesterol levels.
(D) Macrophage-derived 3H-cholesterol content in
plasma, liver, bile, and feces was measured by
liquid scintillation counting. Data analysis shows
that hepatic-specific LXR activation did not alter
the macrophage-mediated RCT. The results are
shown as mean ± SEM (n = 6 for each Ad-infected
animal) and are expressed as percent of radioac-
tivity injected. *p < 0.05 AdVP16LXRa versus
AdVP16.
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to monitor CYP7A1 enzymatic activity (Galman et al., 2003)
(Figures S1F and S1G). Taken together, these data show that
the intestinal activation of LXRa affects plasma lipoproteins,
increases preb-HDL formation, and promotes macrophage-
mediated RCT, which results in enhanced fecal cholesterol
disposal.
Hepatic LXR Activation Does Not Contribute to RCT
Since the liver is also an important player in regulating choles-
terol HDLmetabolism, we checked whether activation of hepatic
LXR could contribute to RCT in vivo.We generated adenoviruses
expressing the same VP16LXRa and VP16 control chimera pro-
teins of the transgenic mice. These viruses were functional in
human cell lines (Figures S2A and S2B). We then injected 5 3
109 pfu/ml of AdVP16 or AdVP16LXRa in the jugular vein of
12-week-old male mice on the same pure strain FVBN back-
ground of the iVP16 and iVP16LXRa mice. Hepatic-specific
LXRa activation induced significant upregulation of all LXR target
genes ABCG5, ABCG8, SREBP1c, FAS, and SCD1 in the liver
(Figure 2A), but not in the intestine (Figure 2B), of AdVP16LXRaCell Metabolism 12, 187–19mice. These molecular events were
coupled with significant increase in both
hepatic and plasma triglycerides (TG)
(most probably induced by the in-
creased hepatic de novo lipogenesis via
SREBP1c activation) with a trend for the
overall decrease in the hepatic choles-
terol (Figure 2C) and no significant
changes in the circulating pre-bHDL
levels (data not shown). The in vivo RCT
experiment revealed the absence of
changes in the radiolabeled index in the
plasma, liver, bile, and fecal cholesterol(Figure 2D). Thus, at a variance of RCT data obtained with
systemic LXR ligands (Naik et al., 2006) and intestinal-specific
LXRa activation (Figure 1I), hepatic-specific LXRa activation
does not promote cholesterol transport in vivo from macro-
phages to feces.
Reduced Hepatic Cholesterol Esters and TG
in iVP16LXRa Mice
To investigate whether iVP16LXRamice are resistant to high die-
tary cholesterol, we challenged these mice with a 2% choles-
terol-enriched diet (Peet et al., 1998). The cholesterol-enriched
diet activated hepatic LXR to similar extent in iVP16LXRa and
iVP16 mice, as shown by the induction in ABCG5-ABCG8
mRNA levels (Figure S3A). Similarly, intestinal ABCA1, ABCG5,
and ABCG8 mRNA levels were upregulated in iVP16 mice and
to a lesser extent also in iVP16LXRamice, where the basal levels
were already induced (Figure S3B). Livers from control mice
showed a change in color saturation and appeared whitish,
a hallmark of lipid accumulation; on the contrary, the color satu-
ration was unmodified in the livers of iVP16LXRamice after high-
cholesterol diet (Figure 3A). Reduced accumulation of hepatic3, August 4, 2010 ª2010 Elsevier Inc. 189
Figure 3. Hepatic and Plasma Cholesterol
and TG Content in iVP16LXRa after High-
Cholesterol Diet
(A) Macroscopic appearance and oil red O staining
of livers from iVP16 and iVP16LXRamice after 2%
cholesterol diet.
(B) Hepatic cholesterol subtypes in iVP16 and
iVP16LXRa mice on high-cholesterol diet. iVP16
mice showed a 30% increase of total liver choles-
terol (TC) amount after high-cholesterol diet com-
pared to iVP16LXRa mice. This difference was
identified as a difference in cholesterol esters
(CE). Free cholesterol (FC) was unmodified.
(C) Hepatic and intestinal ACAT2 enzymatic
activity. Data analysis shows a significant differ-
ence in both hepatic and intestinal ACAT2 activity
between iVP16LXRa and control mice after high-
cholesterol diet.
(D) Hepatic TG content after 2% cholesterol diet.
High-cholesterol diet resulted in a strong increase
of hepatic TG levels in iVP16 mice contrarily to
iVP16LXRa.
(E) The rates of in vivo fatty acids synthesis in the
liver and kidney (extrahepatic control tissue) of
transgenic mice after high-cholesterol diet was
measured 60 min after intraperitoneal injection of
3H-water precursor. iVP16LXRa showed a reduc-
tion in de novo fatty acids after high-cholesterol
diet.
(F) Free cholesterol, cholesterol esters, and TG
lipoprotein measurements after separation by
SEC in iVP16LXRa and iVP16 mice fed a high-
cholesterol diet. iVP16LXRa showed a significant
increase in HDL cholesterol and VLDL-TG parti-
cles compared to control mice, with significant
reduction in VLDL-CE content. The results are
shown as mean ± SEM (n = 6 for each genotype).
*p < 0.05 iVP16LXRa versus VP16.
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confirmed by oil red O analysis (Figure 3A). Hepatic lipid analysis
showed 30% higher total cholesterol amount (TC) of iVP16 mice
after the 2% cholesterol diet compared to iVP16LXRa (Fig-
ure 3B). Also, iVP16LXRa presented significantly lower CE levels
in the liver compared with control iVP16mice, while FC levels did
not change (Figure 3B). To verify whether the observed differ-
ences in CE amount were related to modifications in the activity
of the ACAT2 enzyme, which is a key enzyme involved in the
esterification of cholesterol, ACAT2 activity was analyzed both
in the liver and in the intestine. iVP16LXRa mice presented
a strong reduction in ACAT2 activity, especially in the liver (Fig-
ure 3C). A well-known side effect of systemic LXR activation as
well as of a high-cholesterol diet is the increase of hepatic TG
synthesis. To evaluate whether selective intestinal LXR activa-
tion prevented the increase in hepatic TG in a high-cholesterol
diet, we determined hepatic TG levels in the transgenic mice
after high-cholesterol diet. High-cholesterol diet resulted in
elevated hepatic TG in iVP16 control mice. On the contrary,
iVP16LXRamice showed significantly lower hepatic TG accumu-
lation (Figure 3D). Analysis of the in vivo hepatic fatty acid syn-
thesis confirmed the reduction in the de novo fatty acid synthesis
rate in iVP16LXRa after high-cholesterol diet compared to
control iVP16 mice (Figure 3E). Equal in vivo fatty acid synthesis190 Cell Metabolism 12, 187–193, August 4, 2010 ª2010 Elsevier Incrate in the kidney of both control iVP16 and iVP16LXRa mice
confirmed the hepatic selective response. The analysis of lipo-
protein profiles confirmed the increase in HDL cholesterol in
iVP16LXRa mice and no differences in cholesterol levels in
VLDL and LDL particles (Figure 3F) also during high-cholesterol
diet. In contrast, iVP16LXRamice presented a VLDL fraction pro-
portionally more enriched in TG than that observed in iVP16
mice. The VLDL particles of iVP16LXRa were enriched in TG
to replace the CE that were fewer (Figure 3F), thus being not
atherosclerotic as in the ACAT2/ mouse model (Willner et al.,
2003). Taken together, these data show that intestinal selective
LXR activation protects against high-cholesterol-diet-induced
hepatic steatosis, in the absence of any increase of fatty acid
synthesis.
Antiatherogenic Effects of Intestinal LXR Activation
To investigate whether the observed changes in lipid profile
and increase in RCT affected atherosclerosis, we crossed
iVP16LXRa and iVP16micewith the LDLR/mice. The resulting
iVP16/LDLR/ and iVP16LXRa/LDLR/ mice were fed with
an atherogenic high-fat Western diet for 16 weeks. Intestinal
LXR targets ABCA1, ABCG5, and ABCG8 were significantly up-
regulated by the diet in both iVP16/LDLR/ and iVP16LXRa/
LDLR/ mice (Figure 4A). Quantification of Sudan IV-stained.
Figure 4. Antiatherogenic Effects of Intes-
tinal LXRa Activation
(A) Expression of ABCA1, ABCG5, and ABCG8, in
the intestine of iVP16LXRa/LDLR/ and iVP16/
LDLR/ mice under chow and atherogenic
Western diet was measured by real-time quantita-
tive PCR. The results are shown as mean ± SEM
(n = 6 for each genotype). Different lowercase
letters indicate statistical difference (p < 0.05).
(B and C) En face and aortic root analysis
of atherosclerosis in iVP16LXRa/LDLR/ and
iVP16/LDLR/ mice. Atherosclerotic lesions in
entire aorta and lesion area of aortic root were
quantified as reported in the Supplemental Exper-
imental Procedures. Intestinal-specific activation
of LXRa inhibited the development of atheroscle-
rotic lesions in aorta and aortic root.
(D) iVP16LXRa/LDLR/ and iVP16/LDLR/mice
presented similar levels of atherogenic LDL
cholesterol lipoproteins, with a similar ratio of
FC/CE. Compared to iVP16/LDLR/ mice,
iVP16LXRa/LDLR/ presented a significant
decrease in the VLDL cholesterol levels with lower
CE amounts while showing 15% increase in HDL
cholesterol with higher CE levels. *p < 0.05
iVP16LXRa/LDLR/ versus iVP16/LDLR/.
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in atherosclerotic lesions in iVP16LXRa/LDLR/ mice com-
pared to iVP16/LDLR/mice (Figure 4B). We than analyzed
aortic root sections from male iVP16/LDLR/ and iVP16LXRa/
LDLR/ mice. Quantification of lesions after oil red O staining
disclosed a significant reduction in lesion areas in iVP16LXRa/
LDLR/ mice compared with control iVP16/LDLR/ mice
(Figure 4C). Interestingly, iVP16LXRa/LDLR/ and iVP16/
LDLR/ mice presented similar levels of atherogenic LDL
cholesterol lipoproteins, with a similar ratio of FC/CE (Fig-
ure 4D). On the other hand, compared to iVP16/LDLR/ mice,
iVP16LXRa/LDLR/ presented a significant decrease in the
VLDL cholesterol levels with lower CE amounts while showing
15% increase in HDL cholesterol with higher CE levels. Thus,
the specific activation of LXR in the intestine protects against
atheroclerosis.Cell Metabolism 12, 187–19DISCUSSION
The present work provides clear evidence
of the direct link between intestinal-
specific LXR activation and atheroscle-
rosis protection. The specific intestinal
expression of the constitutively activated
form of LXRa determined the upregula-
tion of intestinal LXR target genes
involved in cholesterol secretion on both
luminal (ABCG5 and ABCG8) and plasma
(ABCA1) compartments. This dual upre-
gulation resulted in a strong reduction of
cholesterol absorption as well as in an
increase of pre-bHDL particles, which
are excellent acceptors of cholesterol
secreted by the macrophages as shownby the upregulation in the RCT pathway. In line with our finding,
elegant pharmacological studies have previously demonstrated
a net induction of the RCT pathway after targeting intestinal
LXR (Brunham et al., 2006b; Peng et al., 2008; Yasuda et al.,
2010). Nevertheless, since even moderate decrease in the intes-
tinal cholesterol absorption rates are associated with a large
atherosclerotic protection (Greenberg et al., 2009), deletion of
NPC1L1 or treatments with ezetimibe in the iVP16LXRa mice
are needed to finally dissect the importance of the apical versus
basolateral enterocyte LXR activation in the protection against
atherosclerosis.
In the present study, we also show that hepatic-specific LXR
activation via adenoviral infection did not induce any significant
changes in the RCT pathway, thus underlining the importance
of the intestine in this respect. Furthermore, using the transgenic
iVP16LXRa mice, we proved that the metabolic effects of3, August 4, 2010 ª2010 Elsevier Inc. 191
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mice were fed a high-cholesterol diet or in iVP16LXRa/LDLR/
mice fed an atherogenic Western diet. Indeed, iVP16LXRa mice
were protected from hepatic cholesterol accumulation. In partic-
ular, hepatic CE was decreased as a consequence of reduced
hepatic ACAT2 activity. In iVP16LXRa, the lower ACAT2 activity
was associated to decreased TG content in the liver (Figures 3C–
3E) and to increased plasma VLDL-TG (Figure 3F). Hence, the
reduction of total hepatic TG and the unaffected in vivo hepatic
fatty acids synthesis were likely due to an increased efflux of
TG from the liver in iVP16LXRamice to replace CE in VLDL (Fig-
ure 3F). Finally, en face and aortic root analysis of iVP16LXRa/
LDLR/ athero-susceptible mice with no changes in athero-
genic LDL cholesterol particles clearly indicated that, together
with the reduced intestinal cholesterol absorption, the increased
synthesis in HDL and the reduction in ACAT2 activity observed in
the intestinal-specific LXR transgenic mice protects from athero-
sclerosis without any side effects such as liver steatosis and
increased fatty acid synthesis.
In conclusion, this work provides the molecular-metabolic
scenario to highlight the critical role of intestinal-specific LXR
activation for the regulation of cholesterol homeostasis in the
body and the potential of this strategy in the treatment of cardio-
vascular disease.EXPERIMENTAL PROCEDURES
Animal Generation, Maintenance, and Treatments
The intestinal-specific VP16LXRa transgenic mice (iVP16LXRa) were gener-
ated by injecting the pSKVillin-VP16LXRa plasmid digested with HpaI into
the pronuclei of the fertilized eggs of FVB/N mice. First, the VP16LXRa
(1.5 Kb) fragment with XhoI and SacII restriction sites was generated by
PCR from the pCMX-VP16LXRa plasmid (kindly provided by Dr. D.J. Mangels-
dorf). Then the fragment was subcloned at the XhoI and SacII restriction sites
downstream of the villin promoter region of the pSKVillin plasmid (kindly
provided by Dr. D. Gumucio). The specific control mice (iVP16) were generated
with the same strategy. The coding sequence of herpes simplex transactiva-
tion domain VP16 was subcloned downstream the villin promoter region of
the pSKVillin plasmid. Liver, kidney, stomach, jejunum, duodenum, ileum,
and colon of transgenic mice were dissected and prepared for total RNA
extraction to evaluate the specific intestinal expression of transgene under
the villin promoter control. Mice were hosted under standard 12 hr light/
12 hr dark cycle and fed standard rodent chow and water ad libitum. Where
indicated, this diet was supplemented with 2% (w/w) cholesterol (DP1014
Altromin; RIEPER; Vandoies, BZ) (Peet et al., 1998). LDLR/ mice on a
C57BL/6 background were obtained from The Jackson Laboratory. LDLR/
mice were crossed with the iVP16LXRa and control iVP16 mice to obtain at
the F2 generation the iVP16LXRa/LDLR/ and the control iVP16/LDLR/
mice in a mixed strain background. These mice were backcrossed for eight
generations to obtain the exact number of mice used in our experiment.
For atherosclerosis studies, iVP16LXRa/LDLR/ or iVP16/LDLR/ crossed
mice were placed on a Western diet (DP1014mod. RIEPER) containing 0.2%
cholesterol and 21.2% fat for 16 weeks prior to sacrifice. Ten- or twelve-
week-old male mice were used in each group of experiments. The Ethical
Committee of the Consorzio Mario Negri Sud approved this experimental
setup, which was also certified by the Italian Ministry of Health in accordance
with internationally accepted guidelines for animal care.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, and three figures and can be found with this article
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